In vivo gene therapy using lentiviral vectors (LVs) has been moving into focus. This review discusses strategies to redirect LV particles to specific cell types through transductional targeting, with special emphasis on vesicular stomatitis virus glycoprotein, its advantages and limitations, current challenges, and potential fields of application, in addition to an overview of ongoing clinical trials.